Celcuity Inc
NASDAQ:CELC
Celcuity Inc
Total Current Liabilities
Celcuity Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celcuity Inc
NASDAQ:CELC
|
Total Current Liabilities
$38.8m
|
CAGR 3-Years
80%
|
CAGR 5-Years
108%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Celcuity Inc
Glance View
Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 39 full-time employees. The company went IPO on 2017-09-20. The firm is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The firm's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).
See Also
What is Celcuity Inc's Total Current Liabilities?
Total Current Liabilities
38.8m
USD
Based on the financial report for Sep 30, 2025, Celcuity Inc's Total Current Liabilities amounts to 38.8m USD.
What is Celcuity Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
108%
Over the last year, the Total Current Liabilities growth was 49%. The average annual Total Current Liabilities growth rates for Celcuity Inc have been 80% over the past three years , 108% over the past five years .
